Wave Life Sciences, Inc.
Every calculator, already run for WVE
Open the full toolkit →You have the numbers on WVE. Get the argument.
A written report on which of these readings actually decide the outcome for Wave Life Sciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
18 analysts covering WVEAnalyst Price Target Disagreement for Wave Life Sciences, Inc.
Wall Street's bull case implies +1044% from the current price; the bear case implies +172%. A 872% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for WVE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was found…
WVE — frequently asked
Is WVE a buy right now?
Wall Street's consensus rating on Wave Life Sciences, Inc. is Strong Buy across 18 analysts, with a mean price target of $18.53 (+405% vs. the current $3.67). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is WVE's next earnings date?
Wave Life Sciences, Inc. is next scheduled to report earnings around Nov 9, 2026. A full WVE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Wave Life Sciences, Inc.?
Analysts covering Wave Life Sciences, Inc. (WVE) range from a bear-case target of $10.00 to a bull-case high of $42.00, with a mean consensus target of $18.53 across 17 analysts. The spread of $32.00 (872% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Wave Life Sciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Wave Life Sciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full WVE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Wave Life Sciences, Inc., in minutes. 3 free reports included with every account — no credit card required.